Dare Bioscience (DARE) announced a live webinar on Wednesday, August 6, 2025, titled “The DARE to PLAY Difference: The Sildenafil Cream That Raises the Bar.” The webinar hosted in collaboration with The National Association of Nurse Practitioners in Women’s Health spotlights a topical formulation of sildenafil – the same active ingredient in Viagra for men – developed specifically for women and clinically shown to improve genital blood flow and sexual response. “Unlike other untested compounded products, DARE to PLAY is backed by clinical evidence and formulated to deliver sildenafil precisely where it can have its effect, closing a long-standing gap between promising science and real solutions for women,” the company said.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DARE:
- Hold Rating on Daré Bioscience: Balancing Promising Product Development with Financial Uncertainties
- 3 Penny Stocks to Watch Now, 7/15/25
- Why Is Daré Bioscience Stock (DARE) Up 240% Today?
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- Douglas Tsao Recommends ‘Buy’ for Daré Bioscience: Ovaprene’s Promising Potential and Financial Prospects